Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 5/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.39 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8344068 | 1.00 | LAP3 (0.45) | LAP3ANPEPSRCBLMCA1 | |
| SCHEMBL7717778 | 0.82 | LAP3 (0.39) | LAP3ANPEPCYP2C19SMN1; SMN2PLAU | |
| SCHEMBL21807707 | 0.80 | SLC6A4 (0.58) | LAP3ANPEPBLM | |
| SCHEMBL3123300 | 0.80 | SLC6A4 (0.58) | LAP3ANPEPBLM | |
| SCHEMBL15720261 | 0.79 | PTPRC (0.56) | LAP3ANPEPSRCBLMSMN1; SMN2 | |
| SCHEMBL15720264 | 0.79 | PTPRC (0.56) | LAP3ANPEPSRCBLMSMN1; SMN2 | |
| Phosphoric Acid SCHEMBL28984077 | 0.78 | SLC7A5 (0.49) | LAP3ANPEPCYP2C19 | |
| SCHEMBL1152 | 0.77 | PTPRC (0.57) | LAP3ANPEPSRCBLMSMN1; SMN2 | |
| SCHEMBL3626587 | 0.77 | PTPRC (0.57) | LAP3ANPEPSRCBLMSMN1; SMN2 | |
| SCHEMBL273663 | 0.77 | PTPRC (0.57) | LAP3ANPEPSRCBLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016042137-A1 | METHOD FOR DIAGNOSING MYELOPROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA OR UNCLASSIFIED MYELOPROLIFERATIVE MYELODYSPLASTIC NEOPLASM | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-24 | — | — | WO | claimed |
| EP-2387586-B1 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | claimed |
| US-20120122120-A1 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR | HOFFMANN-LA ROCHE INC. (US) | 2012-05-17 | — | — | US | claimed |
| EP-2387586-A2 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR | F. Hoffmann-La Roche AG (CH) | 2011-11-23 | — | — | EP | claimed |
| WO-2010081679-A2 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-22 | — | — | WO | claimed |
| US-20100035793-A1 | Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-02-11 | — | — | US | claimed |
| EP-1915162-A4 | MODULATORS | AGENCY SCIENCE TECH & RES (SG) | 2009-08-26 | — | — | EP | claimed |
| EP-1915162-A1 | MODULATORS | Agency for Science, Technology and Research (SG) | 2008-04-30 | — | — | EP | claimed |
| WO-2007013852-A1 | MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY & RESEARCH (SG) | 2007-02-01 | — | — | WO | claimed |
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | COOK PHILLIP D (US) | 2003-04-03 | — | — | US | claimed |
| EP-0739351-A4 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 1998-10-21 | — | — | EP | claimed |
| US-5691305-A | Bone implant composition comprising a porous matrix, bone growth promoter proteins, and phosphotyrosyl protein phosphatase inhibitor | BAYLINK DAVID J (US) | 1997-11-25 | — | — | US | claimed |
| EP-0739351-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-30 | — | — | EP | claimed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | claimed |
| EP-0614530-A4 | INDIRECT IMMUNOASSAY FOR DIOXINLIKE COMPOUNDS. | CORNELL RES FOUNDATION INC (US) | 1995-06-07 | — | — | EP | claimed |
| EP-0614530-A1 | INDIRECT IMMUNOASSAY FOR DIOXINLIKE COMPOUNDS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1994-09-14 | — | — | EP | claimed |
| WO-1993010460-A1 | INDIRECT IMMUNOASSAY FOR DIOXINLIKE COMPOUNDS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0527184-A1 | PHOSPHORAMIDITE DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF IN THE INCORPORATION OF REPORTER GROUPS ON SYNTHETIC OLIGONUCLEOTIDES. | AMERSHAM INT PLC (GB) | 1993-02-17 | — | — | EP | claimed |
| US-4710469-A | DEPHOSPHORIZATING KINASE; ANTITUMOR AND-DIABETIC AGENTS; ATHEROSCLEROSIS | MERCK & CO., INC. (US) | 1987-12-01 | — | — | US | claimed |
| EP-0245979-A2 | Novel phosphotyrosyl protein phosphatase | MERCK & CO. INC. (US) | 1987-11-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | BPGM, PPIP5K2, PGM2 | LAP3 3226/4885ANPEP 1959/4885SRC 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.